We are on a mission to protect the world from cardiovascular disease
Verve Therapeutics is a clinical-stage company developing single-course, in vivo gene editing medicines to permanently lower cardiovascular disease risk. Its platform uses base editing to precisely inactivate genes in the liver — such as PCSK9 and ANGPTL3 — that contribute to atherosclerotic cardiovascular disease. Lead programs VERVE-101 and VERVE-102 are advancing through Phase 1b clinical trials with FDA Fast Track Designation.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountJun 2025
Oct 2024
Jun 2021
Jan 2021
Jun 2020
May 2019
Create a free account to see which investors have funded this company.
Create Free Account
China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
Late-stage biopharma using single-molecule tracking, AI, and engineering to discover and develop ...
Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
